Across TCGA pan-cancer cohorts, LINC01825 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of LINC01825’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LINC01825 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01825 is over-expressed in tumor, although a few such as BLCA and ESCA show the opposite, repressed pattern.

KIRC, KICH, and LUAD are the cancer types where LINC01825 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01825 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.059	.001	5	view →
KICH	All	All	+0.243	.005	4	view →
LUAD	All	All	+0.141	<.001	4	view →
BLCA	All	All	−0.043	.038	2	view →
ESCA	All	All	−0.114	.049	1	view →
HNSC	All	III,IV	−0.051	.024	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: LINC01825 RNA expression & survival · all LINC01825 data types